文献速递白血病

维奈克拉联合阿扎胞苷对比阿扎胞苷单药按高龄与急性髓系白血病复合模型分层的患者结局

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
PubMed 文献 · Leukemia · 2025-09-05

基于VIALE-A三期研究和M14-358一期研究,评估维奈克拉联合阿扎胞苷对比安慰剂联合阿扎胞苷在不适合强化化疗的新诊断急性髓系白血病患者中的疗效与安全性。按年龄(75-79、80-84、≥85岁,汇总n=303)和AML复合模型(AML-CM,A、B、C组,n=380)分层,联合治疗在各年龄和AML-CM组中均改善复合完全缓解和总生存,安全性相似,未发现新安全信号。

要点

  • 维奈克拉联合阿扎胞苷在不适合强化化疗的急性髓系白血病患者中,各年龄和AML-CM组均改善复合完全缓解和总生存。
  • 年龄和AML-CM组间安全性总体相似,未发现新的安全信号。
  • 数据提示无论年龄或衰弱程度,患者均从维奈克拉联合阿扎胞苷中获益,该联合可考虑用于可能被判定为衰弱的急性髓系白血病患者。

核心结论

  • 数据提示无论年龄或衰弱程度,急性髓系白血病患者均从维奈克拉联合阿扎胞苷中获益,该联合可考虑用于可能被判定为衰弱的急性髓系白血病患者。

研究设计与样本

  • 基于VIALE-A三期研究(NCT02993523)和M14-358一期研究(NCT02203773),评估维奈克拉联合阿扎胞苷对比安慰剂联合阿扎胞苷在不适合强化化疗的新诊断急性髓系白血病患者中的疗效与安全性。
  • 按年龄分层:75-79、80-84、≥85岁,汇总两项研究共n=303例。
  • 按AML复合模型(AML-CM,基于合并症估计死亡风险)分层:A、B、C组,来自VIALE-A研究共n=380例。

主要发现

  • 维奈克拉联合阿扎胞苷对比安慰剂联合阿扎胞苷在各年龄组和AML-CM组中均改善复合完全缓解和总生存。
  • 年龄组和AML-CM组间安全性总体相似,未发现新的安全信号。

临床怎么用

  • 作者认为,数据提示无论年龄或衰弱程度,患者均从维奈克拉联合阿扎胞苷中获益,该联合可考虑用于可能被判定为衰弱的急性髓系白血病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax plus azacitidine is recognized as standard of care for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC). However, some patients may still not be treated with venetoclax combinations due to frailty concerns. We evaluated efficacy and safety of venetoclax plus azacitidine vs. placebo plus azacitidine in patients with newly diagnosed AML ineligible for IC from the phase 3 VIALE-A study (NCT02993523) and the phase 1b M14-358 study (NCT02203773), stratified by two methods to potentially assess frailty. The first method was age-based (75-79, 80-84, ≥85 years; n = 303 pooled from both studies) and the second was fitness-based using the AML composite model (AML-CM), a comorbidity-based model to estimate mortality risk (Group A, B, C; n = 380, from VIALE-A). Efficacy, including composite complete remission and overall survival, were improved with venetoclax plus azacitidine vs. placebo plus azacitidine across age and AML-CM groups. Safety was generally similar between age and AML-CM groups and no new safety signals were identified. Taken together, these data suggest that patients benefit from venetoclax plus azacitidine regardless of age or degree of frailty and the combination may be considered for patients with AML who may be deemed frail. Clinical trial information NCT02993523; NCT02203773.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Venditti A, Hou JZ, Fenaux P, et al. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025. PMID: 40913104. doi:10.1038/s41375-025-02730-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。